Linda Yaccarino will become the CEO of eMed Population Health, transitioning from her role at X. She previously worked at NBCUniversal and positively influenced X's ad revenue model. Although she lacks health tech experience, eMed chose her for her strong partnership negotiation skills and her prominence in the tech industry. eMed's previous technology was related to at-home COVID-19 tests, and it is now targeting GLP-1s, drugs effective for weight management and type II diabetes treatment. Yaccarino emphasizes the need for tenacity in leading healthcare reform.
Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network's troubled ad revenue model.
To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry.
eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes.
eMed said in a press release that they sought her out for her "undeniable ability to negotiate new partnerships" - it certainly also helps that her tenure at X made her well-known in the tech world.
Collection
[
|
...
]